Stockhouse19 天
Regeneron to Advance Two Factor XI Antibodies into a Broad Phase 3 Program Following ...
TARRYTOWN, N.Y., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced positive Phase 2 results for two novel monoclonal antibodies targeting distinct ...